Roche Holding AG
- Country
- ๐จ๐ญSwitzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab (TCZ) Administered to Participants With Giant Cell Arteritis (GCA).
- First Posted Date
- 2019-04-23
- Last Posted Date
- 2021-12-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 24
- Registration Number
- NCT03923738
- Locations
- ๐จ๐ญ
Universitรคtsspital Basel; Rheumatologie, Basel, Switzerland
๐จ๐ญInselspital Bern; Rheumatologie; Klinische Immunologie und Allergologie, Bern, Switzerland
A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia
- First Posted Date
- 2019-04-22
- Last Posted Date
- 2022-02-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 13
- Registration Number
- NCT03922477
- Locations
- ๐บ๐ธ
MD Anderson Cancer Center, Houston, Texas, United States
๐บ๐ธUC Davis Comprehensive Cancer Center, Sacramento, California, United States
๐บ๐ธYale, New Haven, Connecticut, United States
A Study to Investigate the Safety and Efficacy of Atezolizumab in Previously-Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- First Posted Date
- 2019-04-22
- Last Posted Date
- 2022-09-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 101
- Registration Number
- NCT03922997
- Locations
- ๐จ๐ณ
Peking Union Medical College Hospital, Beijing City, China
๐จ๐ณSichuan Cancer Hospital, Chengdu City, China
๐จ๐ณHarbin Medical University Tumor Hospital; Department of Surgery; Pharmacy, Harbin, China
A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics and Safety and Tolerability of a Single Oral Dose of Risdiplam Compared to Matched Healthy Participants With Normal Hepatic Function
- First Posted Date
- 2019-04-19
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 26
- Registration Number
- NCT03920865
- Locations
- ๐บ๐ธ
Clinical Pharmacology of Miami, Inc., Miami, Florida, United States
๐บ๐ธOrlando Clinical Research Center, Orlando, Florida, United States
๐บ๐ธAmerican Research Corporation Inc., San Antonio, Texas, United States
The Effect of Hepatic Impairment on the Pharmacokinetics of Balovaptan
- First Posted Date
- 2019-04-11
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT03912350
A Study to Evaluate Safety and Therapeutic Activity of RO6874281 in Combination with Pembrolizumab, in Participants with Advanced or Metastatic Melanoma
- First Posted Date
- 2019-03-14
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 83
- Registration Number
- NCT03875079
- Locations
- ๐บ๐ธ
Dana Farber Cancer Institute, Boston, Massachusetts, United States
๐ซ๐ทCentre Eugene Marquis; Service d'oncologie, Rennes, France
๐ซ๐ทInstitut Gustave Roussy; Dermatologie, Villejuif, France
Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)
- First Posted Date
- 2019-03-11
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 645
- Registration Number
- NCT03869190
- Locations
- ๐ช๐ธ
START Madrid. Centro Integral Oncologico Clara Campal; CIOCC, Madrid, Spain
๐ช๐ธHospital Clinico Universitario de Valencia, Valencia, Spain
๐จ๐ณNational Taiwan University Hospital, Yun-Lin Branch, Huwei Township, Taiwan
A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2019-03-07
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 47
- Registration Number
- NCT03866239
- Locations
- ๐ซ๐ท
Centre Leon Berard; Departement Oncologie Medicale, Lyon, France
๐บ๐ธStanford Comprehensive Cancer Center, Stanford, California, United States
๐ช๐ธSTART Madrid-FJD, Hospital Fundacion Jimenez Diaz, Madrid, Spain
A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission
- Conditions
- Interventions
- First Posted Date
- 2019-02-21
- Last Posted Date
- 2022-06-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 24
- Registration Number
- NCT03850535
- Locations
- ๐บ๐ธ
Massachusetts General Hospital, Boston, Massachusetts, United States
๐บ๐ธSarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
๐บ๐ธUCLA Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
A 2 Part Study to Assess the Relative Bioavailability of Tablet Formulation Compared to Capsule Formulation and the Effect of Food and Taste Assessment on the Tablet Formulation in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2019-02-20
- Last Posted Date
- 2020-05-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 24
- Registration Number
- NCT03847987
- Locations
- ๐บ๐ธ
PRA Health Sciences, Salt Lake City, Utah, United States